Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 19/20 | 0.71 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.65 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.65 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896426 | 0.84 | MAP4K4 (0.65) | MAP4K4MINK1TNIK | |
| SCHEMBL15587577 | 0.83 | MAP4K4 (0.70) | MAP4K4MINK1TNIK | |
| SCHEMBL15587252 | 0.83 | MAP4K4 (1.00) | MAP4K4MINK1TNIK | |
| SCHEMBL31060266 | 0.83 | MAP4K4 (1.00) | MAP4K4MINK1TNIK | |
| SCHEMBL15587992 | 0.83 | MAP4K4 (1.00) | MAP4K4MINK1TNIK | |
| SCHEMBL4115100 | 0.82 | MAP4K4 (0.52) | MAP4K4MINK1TNIKTGFBR1 | |
| SCHEMBL15587400 | 0.81 | MAP4K4 (0.75) | MAP4K4MINK1TNIK | |
| SCHEMBL8258718 | 0.81 | MAP4K4 (0.48) | MAP4K4MINK1TNIK | |
| SCHEMBL4112969 | 0.81 | MAP4K4 (0.48) | MAP4K4MINK1TNIK | |
| SCHEMBL4109988 | 0.81 | MAP4K4 (0.48) | MAP4K4MINK1TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | claimed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | claimed |
| EP-2855459-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | claimed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | claimed |
| US-20130324516-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH INC (US) | 2013-12-05 | — | — | US | claimed |
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-2855459-B1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| EP-2855459-B1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899332-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006135993-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. | GILEAD SCIENCES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324516-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | ABL1, CDK2, PDXK | MAP4K4 142/4885MINK1 3087/4885TNIK 1732/4885 |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | MAP4K4 3289/4885MINK1 3501/4885TNIK 2895/4885 |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | MAP4K4 700/4885MINK1 3176/4885TNIK 2475/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885MINK1 3194/4885TNIK 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.